Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated

Maze Therapeutics, Inc.

2025-Q1 EPS reported -$1.15

Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.
Net loss of $32.8M for Q1 2025, vs $32.5M in Q1 2024; R&D expenses $27.6M (up from $21.9M).
MZE829 Phase 2 HORIZON trial enrolling APOL1 kidney disease patients; initial proof-of-concept data expected Q1 2026.
MZE782 Phase 1 healthy volunteer trial ongoing; initial biomarker data expected Q3 2025.
Cash increase largely from IPO proceeds; no revenue reported (clinical-stage biotech).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.